Clonidine causes antidepressant-like effects in rats by activating alpha 2-adrenoceptors outside the locus coeruleus.
Clonidine, 0.05, 0.1 and 0.5 mg/kg administered i.p. as a three-injection course but not as single doses, significantly reduced the immobility of rats in the forced swimming test. Doses of 0.1 and 0.5, administered the same way, significantly reduced activity in an open field. The effect of 0.05 and 0.5 mg/kg clonidine on immobility was prevented by 1 mg/kg idazoxan, an alpha 2-adrenoceptor antagonist, but not by 3 mg/kg prazosin, which blocks alpha 1-adrenoceptors. An infusion of 6 micrograms/microliters 6-hydroxydopamine in the locus coeruleus, which markedly depleted noradrenaline in terminal regions, did not modify the effect of 0.05 and 0.5 mg/kg clonidine on immobility. Chronic treatment with 5 mg/kg i.p. desipramine or 0.1 mg/kg i.p. clonidine, twice daily for 15 days, did not modify the effect of a three-injection course with 0.1 mg/kg clonidine. It is suggested that clonidine exerts antidepressant-like effects on rats in the forced swimming test by acting on central alpha 2-adrenoceptors outside the locus coeruleus and presumably postsynaptically to noradrenaline-containing neurons. No tolerance or sensitization of the clonidine effect was found after chronic treatment with desipramine or clonidine. These findings are of significance for the effects of clonidine in subgroups of depressed patients.
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
L
L
Cervo
R
R
Samanin
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D003000:Clonidine / Q000008:administration & dosage / Q000494:pharmacology*; D003891:Desipramine / Q000494:pharmacology; D004146:Dioxanes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006892:Hydroxydopamines / Q000494:pharmacology; D019329:Idazoxan; D008125:Locus Coeruleus / Q000166:cytology / Q000187:drug effects* / Q000648:ultrastructure; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D009638:Norepinephrine / Q000378:metabolism; D016627:Oxidopamine; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects* / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D000928:Antidepressive Agents; D004146:Dioxanes; D006892:Hydroxydopamines; D011942:Receptors, Adrenergic, alpha; D016627:Oxidopamine; D003000:Clonidine; D003891:Desipramine; D009638:Norepinephrine; D011224:Prazosin; D019329:Idazoxan